albuterol (Armstrong Albuterol HFA) + Albuterol Sulfate (Provenetil-HFA) + Placebo-HFA
Phase 3Terminated 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma, Bronchospasm
Trial Timeline
Feb 1, 2008 โ Oct 1, 2008
NCT ID
NCT00634829About albuterol (Armstrong Albuterol HFA) + Albuterol Sulfate (Provenetil-HFA) + Placebo-HFA
albuterol (Armstrong Albuterol HFA) + Albuterol Sulfate (Provenetil-HFA) + Placebo-HFA is a phase 3 stage product being developed by Amphastar Pharmaceuticals for Asthma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00634829. Target conditions include Asthma, Bronchospasm.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00634829 | Phase 3 | Terminated |
Competing Products
20 competing products in Asthma
Other Products from Amphastar Pharmaceuticals
E004 (Epinephrine Inhalation Aerosol) HFA-MDI + Placebo-HFAPhase 3
72
Placebo + Primatene Mist + Epinephrine inhalationPhase 3
72
Armstrong Albuterol Sulfate Inhalation Aerosol + Albuterol Sulfate Inhalation AerosolPhase 3
72
albuterol HFA (Armstrong's) + albuterol HFA (Proventil HFA) + HFA placeboPhase 3
72
Epinephrine HFA-MDI (E004) + Placebo-HFAPhase 3
72